Faculty profile

Pierre Billon

ResearcherBiochemistry and Molecular BiologyUniversity of Calgary

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Calgary directory, so their courses may be missing. Find their university profile.

Pierre Billon

Researcher

Biochemistry and Molecular Biology

Health Sciences

University of Calgary

Calgary, Alberta, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
8 publications in the last five years, latest in 2026.
Senior (last) author on 3 recent papers, a sign of leading a research group.
Principal investigator on 3 research grants (2 NSERC, 1 CIHR), most recently in 2024.
Supervised 3 trainees who won CIHR awards, most recently in 2025.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Crispr-Cas9 Dna Repair Functional Genomics Genome Editing Genomic Stability Mass Spectrometry Pcna Post-Translational Modifications

Latest papers

Compound delivery of eVLPs enhances prime editing for targeted genome engineering and high-throughput screening.
Cell genomics · 2026 · senior author
GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.
Nature cancer · 2026
FAME-CRISPR improves CRISPR-Cas9 genome editing via HDAC inhibition and engineered virus-like particle delivery.
Cell reports methods · 2026

All 9 publications

Latest funding

Repurposing a clinically approved safety switch to engineer exhaustion resistant CAR-T cells
CIHR · 2025 · Supervisor
$120,000
VIVO-EDIT: In Vivo Engineering of Multiplex-Edited CAR-T Cells Using Virus-Like Particles for Cancer Immunotherapy
CIHR · 2025 · Supervisor
$120,000
Building the First Made-in-Canada Base Editing Pipeline for Inborn Errors of Immunity: Proof-of-Concept in ADA-SCID Q3X
CIHR · 2025 · Supervisor
$140,000

All 8 grants and awards

9 publications.

Compound delivery of eVLPs enhances prime editing for targeted genome engineering and high-throughput screening.

Langley J, Baudrier L, Curry J, Narta K, Todesco HM, Potts K, Morrissy S, Mahoney DJ, Billon P

Cell genomics2026Senior author

DOI: 10.1016/j.xgen.2026.101302 PMID: 42447864

GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.

Zemp FJ, Breckenridge Z, Song H, Gill GS, Louie TL, Narta K, Liu H, Suh Y, Guignard L, Mandujano-Tinoco EA, Collao N, Pyczek J, Ellestad KK, Curry J, Langley J, John C, Mah LK, Rajwani J, Evseev D, Turk M, Benaoudia S, Alex J, Naumenko V, Manoharan VT, Mehrabadi MK, Smith HA, Gilbert GNY, Gillmor A, Verhey TB, Todesco HM, Osz K, Ahn BY, Bogossian A, Anderson C, Sikdar S, Rukunuddin S, Bismar TA, Heng DYC, Lawson K, Linehan WM, Pedersen H, Gordon PMK, McIntyre JB, MacGregor J, Garzia L, Brodeur-Robb K, DiFrancesco L, Ogilvie T, Schöffski P, Wozniak A, Holt RA, Bell J, Senger DL, Lewis V, Monument M, Khan O, Baudrier L, Billon P, Gabriel V, Biernaskie J, Potts K, Trpkov K, Hay K, Quizi J, Chan J, Saleh R, Henning JW, Prokopishyn NL, Shafey M, Morrissy AS, Mahoney DJ

Nature cancer2026

DOI: 10.1038/s43018-026-01194-3 PMID: 42387022

FAME-CRISPR improves CRISPR-Cas9 genome editing via HDAC inhibition and engineered virus-like particle delivery.

Djamshidi M, Hill A, Heshmatzad K, Langley J, Krowicki H, Ali M, Yang Y, Tanida R, Abdul-Careem MF, Billon P, Riabowol K

Cell reports methods2026

DOI: 10.1016/j.crmeth.2025.101248 PMID: 41344324

CHD6 has poly(ADP-ribose)- and DNA-binding domains and regulates PARP1/2-trapping inhibitor sensitivity via abasic site repair.

Provencher L, Nartey W, Brownlee PM, Atkins AW, Gagné JP, Baudrier L, Ting NSY, Piett CG, Fang S, Pearson DD, Moore S, Billon P, Nagel ZD, Poirier GG, Williams GJ, Goodarzi AA

Nature communications2025

DOI: 10.1038/s41467-025-56085-5 PMID: 39863586

A protocol for the detection of precision genome editing in human cells using One-pot DTECT.

Langley J, Baudrier L, Billon P

STAR protocols2024Senior author

DOI: 10.1016/j.xpro.2024.103307 PMID: 39292561

TULIPs decorate the three-dimensional genome of PFA ependymoma.

Johnston MJ, Lee JJY, Hu B, Nikolic A, Hasheminasabgorji E, Baguette A, Paik S, Chen H, Kumar S, Chen CCL, Jessa S, Balin P, Fong V, Zwaig M, Michealraj KA, Chen X, Zhang Y, Varadharajan S, Billon P, Juretic N, Daniels C, Rao AN, Giannini C, Thompson EM, Garami M, Hauser P, Pocza T, Ra YS, Cho BK, Kim SK, Wang KC, Lee JY, Grajkowska W, Perek-Polnik M, Agnihotri S, Mack S, Ellezam B, Weil A, Rich J, Bourque G, Chan JA, Yong VW, Lupien M, Ragoussis J, Kleinman C, Majewski J, Blanchette M, Jabado N, Taylor MD, Gallo M

Cell2024

DOI: 10.1016/j.cell.2024.06.023 PMID: 38986619

One-pot DTECT enables rapid and efficient capture of genetic signatures for precision genome editing and clinical diagnostics.

Baudrier L, Benamozig O, Langley J, Chopra S, Kalashnikova T, Benaoudia S, Singh G, Mahoney DJ, Wright NAM, Billon P

Cell reports methods2024Senior author

DOI: 10.1016/j.crmeth.2024.100698 PMID: 38301655

CRISPR-based genome editing through the lens of DNA repair.

Nambiar TS, Baudrier L, Billon P, Ciccia A

Molecular cell2022

DOI: 10.1016/j.molcel.2021.12.026 PMID: 35063100

A detection method for the capture of genomic signatures: From disease diagnosis to genome editing.

Benamozig O, Baudrier L, Billon P

Methods in enzymology2021Senior author

DOI: 10.1016/bs.mie.2021.08.012 PMID: 34776215

Repurposing a clinically approved safety switch to engineer exhaustion resistant CAR-T cells

SupervisorCIHR2025DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

Principal investigators: Curry, Jada

Keywords: Car-T Therapies; Crispr/Cas9 Technologies; Genome Editing; Immune Cell Engineering; Immunotherapy

$120,000

VIVO-EDIT: In Vivo Engineering of Multiplex-Edited CAR-T Cells Using Virus-Like Particles for Cancer Immunotherapy

SupervisorCIHR2025DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

Principal investigators: Langley, Jethro

Keywords: Cancer Therapies; Car-T Cell Therapy; Crispr Technologies; Genome Editing; Immune Cell Engineering; In Vivo Genome Editing; Leukemia; Synthetic Biology; Viral Vectors; Virus-Like Particles

$120,000

Building the First Made-in-Canada Base Editing Pipeline for Inborn Errors of Immunity: Proof-of-Concept in ADA-SCID Q3X

SupervisorCIHR2025Canada Postdoctoral Research Award (CPRA) program

Principal investigators: Mashayekhi, Fatemeh

Keywords: Adenosine Deaminase; Base Editing; Crispr; Genome Editing; Inborn Errors Of Immunity; Lipid Nanoparticles (Lnp)

$140,000

Defining the interplay between DNA repair and CRISPR-based genome editing technologies

Principal investigatorNSERC2024Discovery Launch Supplement

Principal investigators: Billon, Pierre

Keywords: genome editing; dna repair; crispr-cas9; base editing; mismatch repair; base excision repair; dsb repair

$12,500

Defining the interplay between DNA repair and CRISPR-based genome editing technologies

Principal investigatorNSERC2024Discovery Grants Program - Individual

Principal investigators: Billon, Pierre

Keywords: genome editing; dna repair; crispr-cas9; base editing; mismatch repair; base excision repair; dsb repair

$46,000

High-throughput Functional Dissection of PCNA Modifications that Promote Genome Stability in Human Cells

Nominated PICIHR2023Project Grant

Principal investigators: Billon, Pierre; Schriemer, David C

Keywords: Crispr-Cas9; Dna Repair; Functional Genomics; Genome Editing; Genomic Stability; Mass Spectrometry; Pcna; Post-Translational Modifications; Prime Editing

$914,175

A pilot project to demonstrate feasibility of a Canadian gene therapy clinical trials platform for rare genetic diseases: Gene Therapy for CD3delta Severe Combined Immune Deficiency.

Co-investigatorCIHR2022Operating Grant: Clinical Trials Projects - Indirect Costs

Principal investigators: Wright, Nicola A; Cuvelier, Geoff; Grunebaum, Eyal; Guilcher, Greg; Kohn, Donald B; Lewis, Victor; Marwaha, Ashish K; Murguia-Favela, Luis E; Narendran, Aru; Prokopishyn, Nicole L; Romero Garcia, Zulema; Suresh, Sneha

Keywords: Adenine Base Editing; Gene Editing; Gene Therapy Clinical Trial; Inborn Errors Of Immunity; Rare Diseases; Severe Combined Immune Deficiency

$606,576

A pilot project to demonstrate feasibility of a Canadian gene therapy clinical trials platform for rare genetic diseases: Gene Therapy for CD3delta Severe Combined Immune Deficiency.

Co-investigatorCIHR2022Operating Grant: Clinical Trials Projects

Keywords: Adenine Base Editing; Gene Editing; Gene Therapy Clinical Trial; Inborn Errors Of Immunity; Rare Diseases; Severe Combined Immune Deficiency

$2,426,302

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Pierre Billon

Research

Latest papers

Latest funding

Compound delivery of eVLPs enhances prime editing for targeted genome engineering and high-throughput screening.

GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.

FAME-CRISPR improves CRISPR-Cas9 genome editing via HDAC inhibition and engineered virus-like particle delivery.

CHD6 has poly(ADP-ribose)- and DNA-binding domains and regulates PARP1/2-trapping inhibitor sensitivity via abasic site repair.

A protocol for the detection of precision genome editing in human cells using One-pot DTECT.

TULIPs decorate the three-dimensional genome of PFA ependymoma.

One-pot DTECT enables rapid and efficient capture of genetic signatures for precision genome editing and clinical diagnostics.

CRISPR-based genome editing through the lens of DNA repair.

A detection method for the capture of genomic signatures: From disease diagnosis to genome editing.

Repurposing a clinically approved safety switch to engineer exhaustion resistant CAR-T cells

VIVO-EDIT: In Vivo Engineering of Multiplex-Edited CAR-T Cells Using Virus-Like Particles for Cancer Immunotherapy

Building the First Made-in-Canada Base Editing Pipeline for Inborn Errors of Immunity: Proof-of-Concept in ADA-SCID Q3X

Defining the interplay between DNA repair and CRISPR-based genome editing technologies

Defining the interplay between DNA repair and CRISPR-based genome editing technologies

High-throughput Functional Dissection of PCNA Modifications that Promote Genome Stability in Human Cells

A pilot project to demonstrate feasibility of a Canadian gene therapy clinical trials platform for rare genetic diseases: Gene Therapy for CD3delta Severe Combined Immune Deficiency.

A pilot project to demonstrate feasibility of a Canadian gene therapy clinical trials platform for rare genetic diseases: Gene Therapy for CD3delta Severe Combined Immune Deficiency.

Frequent collaborators

John Bell

Nada Jabado

Mathieu Lupien

Mathieu Blanchette

Karl Riabowol

Jennifer Chan

Jacek Majewski

Guillaume Bourque

Marco Gallo

Claudia Kleinman

Michael Monument

Livia Garzia

Sorana Morrissy

Ramy Saleh

Jennifer Quizi

Victor Lewis

Mona Shafey

Kevin Hay